Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-29
2009-10-06
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S315000, C544S358000, C546S184000
Reexamination Certificate
active
07598249
ABSTRACT:
Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
REFERENCES:
patent: 3813395 (1974-05-01), Nakanishi et al.
patent: 6096784 (2000-08-01), Lerner et al.
patent: 6100279 (2000-08-01), Vaccaro et al.
patent: 6462054 (2002-10-01), Boger
patent: 2003/0187040 (2003-10-01), Pevarello et al.
patent: 2004/0220191 (2004-11-01), Schwink et al.
patent: 2006/0014830 (2006-01-01), Abouabdellah et al.
patent: 2006/0089344 (2006-04-01), Abouabdellah et al.
patent: 48010160 (1973-03-01), None
patent: 11139969 (1999-05-01), None
patent: WO 93/00342 (1993-01-01), None
patent: WO 96/09817 (1996-04-01), None
patent: WO 96/21648 (1996-07-01), None
patent: WO 97/23458 (1997-07-01), None
patent: WO 97/42230 (1997-11-01), None
patent: WO 97/49667 (1997-12-01), None
patent: WO 98/37077 (1998-08-01), None
patent: WO 99/24421 (1999-05-01), None
patent: WO 99/26584 (1999-06-01), None
patent: WO 99/42107 (1999-08-01), None
patent: WO 01/36386 (2001-05-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/087569 (2002-11-01), None
patent: WO 03/047569 (2003-06-01), None
patent: WO 03/065989 (2003-08-01), None
patent: WO 2004/033652 (2004-04-01), None
patent: WO 2004/067498 (2004-08-01), None
patent: WO 2004/072025 (2004-08-01), None
patent: WO 2004/099176 (2004-11-01), None
Janzten and Robinson, Modern Pharmaceutics, 1996, p. 596.
“Metabolite-encyclopedia.com”, http://www.encyclopedia.com/doc/1E1-metabolit.html, accessed Jan. 25, 2008.
Hertzog. Expert Opinion in Therapeutic Patents, 2004, 14(10), 1435-52.
Vaccaro et al., 2006, vol. 16 (2), pp. 395-399. Bioorg. Med. Chem. Lett.
Baker et al., “Cannabinoids controls spasticity and tremor in a multiple sclerosis model,”Nature2000, 404, 84-87.
Baker et al., “Endocannabinoids control spasticity in a multiple sclerosis model,”FASEB J.2001, 15(2), 300-302.
Boger et al., “Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: A probe of structural and conformational features contributing to inhibition,”Bioorg. Med. Chem. Lett.1999, 9, 265-270.
Boger et al., “Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide,”Proc. Natl. Acad. Sci. USA2000, 97(10), 5044-5049.
Boger et al., “α-Keto heterocycle inhibitors of fatty acid amide hydrolase: Carbonyl group modification and α-substitution,”Bioorg. Med. Chem. Lett.2001, 11, 1517-1520.
Cravatt et al., “Chemical characterization of a family of brain lipids that induce sleep,”Science1995, 268(5216), 1506-1509.
Cravatt et al., “Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides,”Nature1996, 384(6604), 83-86.
Cravatt et al., “Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase,”Proc. Natl. Acad. Sci. USA2001, 98(16), 9371-9376.
Devane et al., “Isolation and structure of a brain constituent that binds to the cannabinoid receptor,”Science1992, 258(5090), 1946-1949.
Goya et al., “Recent advances in cannabinoid receptor agonists and antagonists,”Exp. Opin. Ther. Patents2000, 10(10), 1529-1538.
Kathuria et al., “Modulation of anxiety through blockade of anandamide hydrolysis,”Nat. Med.2003, 9(1), 76-81.
Kirkham et al., “Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of feeding by 2-arachidonyl glycerol,”Br. J. Pharmacol.2002, 136, 550-557.
Lambert et al., “The palmitoylethanolamide family: A new class of anti-inflammatory agents?”Curr. Med. Chem.2002, 9(6), 663-674.
Mendelson et al., “The hypnotic actions of the fatty acid amide, oleamide,”Neuropsychopharmacology2001, 25(S5), S36-S39.
Piomelli, “The molecular logic of endocannabinoid signalling,”Nat. Rev. Neurosci.2003, 4(11), 873-884.
Robson, “Therapeutic aspects of cannabis and cannabinoids,”Br. J. Psychiatry2001, 178, 107-115.
Svendsen et al., “Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial,”Br. Med. J.2004, 329(7460), 253-260.
Tarzia et al., “Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors,”J. Med. Chem.2003, 46, 2352-2360.
Ueda et al., “Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance,”J. Biol. Chem.2001, 276(38), 35552-35557.
Vaccaro et al., “Novel Histamine H3Receptor Antagonists Based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold,”Bioorg. Med. Chem. Lett.2006, 16(2), 395-399.
Baker et al., “The Therapeutic Potential of Cannabis in Multiple Sclerosis,” Expert Opin Investig Drugs. 2003, 12, 561-567.
Barann et al., “Direct Inhibition by Cannabinoids of Human 5-HT3A Receptors: Probable Involvement of an Allosteric Modulatory Site,” Br J Pharmacol. 2002, 137, 589-596.
Bisogno et al., “Fatty Acid Amide Hydrolase, an Enzyme with Many Bioactive Substrates. Possible Therapeutic Implications,” Curr Pharm Des. 2002, 8, 533-47.
Boger et al., “Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules,” Curr Pharm Des. 1998, 4, 303-314.
Bracey et al., “Structural adaptations in a membrane enzyme that terminates Endocannabinoid Signaling,” Science 2002, 298, 1793-96.
Croxford, “Therapeutic potential of cannabinoids in CNS Disease,” CNS Drugs 2003, 17, 179-202.
Dinh et al., “Brain monoglyceride lipase participating in endocannabinoid inactivation,” PNAS, 2002, 99, 10819-24.
Fowler et al., “Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide,” Biochem Pharmacol. 2001, 62, 517-26.
Giang et al., “Molecular characterization of human and mouse fatty acid amide hydrolases,” PNAS 1997, 94, 2238-42.
Howlett et al., “International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors,” Pharmacol Rev. 2002, 54, 161-202.
Lambert et al., “The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?,” Curr Med Chem. 1999, 6, 757-73.
Olah et al., “Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1,” J Biol Chem. 2001, 276, 31163-70.
Quistad et al., “Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications,” Toxicol Appl Pharmacol. 2002, 179, 57-63.
Rodriquez de Fonseca et al., “An anorexic lipid mediator regulated by feeding,” Nature 2001, 414, 209-12.
Savinainen et al., “Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes,” Br J Pharmacol. 2001, 134, 664-72.
Stamer et al., “Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues,” Eur J Pharmacol. 2001, 431, 277-86.
Sugiura et al., “Evidence that 2-arachidonoylglycerol but not N-pa
Apodaca Richard
Breitenbucher J. Guy
Pattabiraman Kanaka
Seierstad Mark
Xiao Wei
Atkins Michael J.
Janssen Pharmaceutica N.V.
Jarrell Noble
Wilson James O
LandOfFree
Piperazinyl and piperidinyl ureas as modulators of fatty... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazinyl and piperidinyl ureas as modulators of fatty..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinyl and piperidinyl ureas as modulators of fatty... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079564